Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Advanced Drainage Systems Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Advanced Drainage Systems Inc trades at $145.16 (market cap $11.42B). The key difference: Advanced Drainage Systems Inc is far larger — about 2.5× ACADIA Pharmaceuticals Inc.'s market cap, and Advanced Drainage Systems Inc pays a 0.54% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WMS | |
|---|---|---|
Market Cap | $4.49B | $11.42B |
Sector | Health | Industrials |
52-Week High | $28.06 | $175.38 |
52-Week Low | $20.06 | $110.89 |
Enterprise Value | $3.69B | $12.99B |
Dividend Yield | — | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Advanced Drainage Systems (WMS) trades at $149.07, down 2.04% over 24 hours. The stock shows strong profitability with a 13.98% net income margin and consistent earnings beats in recent quarters. Technical indicators are bullish overall, with moving averages supporting an uptrend. Recent news includes a dividend increase and mixed analyst sentiment, with a consensus price target of $183.00. Cash flow trends indicate robust operational performance despite a recent dip in net cash flow.
Outlook remains positive due to solid fundamentals and growth in stormwater management demand. Risks include competitive pressures and potential margin compression. The stock presents a moderate buy opportunity with upside to analyst targets, balanced by near-term volatility and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
